Regeneron Pharmaceuticals, Inc. XNAS: REGN

Regeneron Pharma Live Stock Price Today, Share Analysis and Chart

Name: Regeneron Pharmaceuticals, Inc.: Is Infosys Ltd. worth buying?
Item: Regeneron Pharmaceuticals, Inc.
Rating: 2.397569375
Author: Trendlyne DVM scores

Turnaround Potential

about

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet ag...

763.70 1.05 (0.14%)

60.28% Gain from 52W Low

228.0K

XNAS Volume

XNAS 27 Jan, 2026 12:53 PM (EST)

Board Meeting

The next board meeting for Regeneron Pharma is on 05 Feb 2026 for the purpose of Regeneron Pharmaceuticals Inc Annual Report for 2025 See details

Medium Financial Strength

44.4 / 100

Mid Valuation

41.7 / 100

Technically Moderately Bullish

61.3 / 100

Turnaround Potential These stocks have average financials and valuation, but strong momentum indicating buying interest View Similar Embed DVM

831

1Yr Price target upside is 9%

26 analysts

Regeneron Pharma Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Regeneron Pharma Live Stock Price Today, Share Analysis and Chart

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet ag...

60.28% Gain from 52W Low

SWOT Analysis

Regeneron Pharma Live Price Chart